| scholarly article | Q13442814 |
| P50 | author | Zeger Debyser | Q47494689 |
| Frauke Christ | Q75662430 | ||
| P2093 | author name string | Arnaud Marchand | |
| Patrick Chaltin | |||
| Mike Westby | |||
| Stephen Shaw | |||
| Jonas Demeulemeester | |||
| Chris Pickford | |||
| Wim Smets | |||
| Scott Butler | |||
| Belete A Desimmie | |||
| P2860 | cites work | Transient and stable knockdown of the integrase cofactor LEDGF/p75 reveals its role in the replication cycle of human immunodeficiency virus | Q24538808 |
| Retroviral intasome assembly and inhibition of DNA strand transfer | Q24629737 | ||
| Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137) | Q24656978 | ||
| LEDGF/p75 functions downstream from preintegration complex formation to effect gene-specific HIV-1 integration | Q24671948 | ||
| Crystal structure of the HIV-1 integrase catalytic core and C-terminal domains: A model for viral DNA binding | Q27625292 | ||
| Rational design of small-molecule inhibitors of the LEDGF/p75-integrase interaction and HIV replication | Q27661671 | ||
| Lersivirine, a Nonnucleoside Reverse Transcriptase Inhibitor with Activity against Drug-Resistant Human Immunodeficiency Virus Type 1 | Q27663609 | ||
| HIV Capsid is a Tractable Target for Small Molecule Therapeutic Intervention | Q27666355 | ||
| Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study | Q48565770 | ||
| Resistance associated mutations to dolutegravir (S/GSK1349572) in HIV-infected patients--impact of HIV subtypes and prior raltegravir experience. | Q51585550 | ||
| Elvitegravir: a once daily alternative to raltegravir | Q82120431 | ||
| Multimode, Cooperative Mechanism of Action of Allosteric HIV-1 Integrase Inhibitors | Q27678141 | ||
| New Class of HIV-1 Integrase (IN) Inhibitors with a Dual Mode of Action | Q27678745 | ||
| HIV-1 integrase forms stable tetramers and associates with LEDGF/p75 protein in human cells | Q28212168 | ||
| An essential role for LEDGF/p75 in HIV integration | Q28262502 | ||
| Identification and characterization of a functional nuclear localization signal in the HIV-1 integrase interactor LEDGF/p75 | Q28263591 | ||
| Identification of an evolutionarily conserved domain in human lens epithelium-derived growth factor/transcriptional co-activator p75 (LEDGF/p75) that binds HIV-1 integrase | Q28282487 | ||
| Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives | Q28323202 | ||
| Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds | Q28339318 | ||
| The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability | Q29547634 | ||
| Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone | Q29547734 | ||
| Retroviral DNA integration: viral and cellular determinants of target-site selection | Q33247467 | ||
| Virus evolution reveals an exclusive role for LEDGF/p75 in chromosomal tethering of HIV. | Q33280633 | ||
| An allosteric mechanism for inhibiting HIV-1 integrase with a small molecule | Q33488152 | ||
| A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1 | Q33979107 | ||
| Structural basis for the recognition between HIV-1 integrase and transcriptional coactivator p75. | Q34161123 | ||
| LEDGF/p75-independent HIV-1 replication demonstrates a role for HRP-2 and remains sensitive to inhibition by LEDGINs | Q34186964 | ||
| Phage display-directed discovery of LEDGF/p75 binding cyclic peptide inhibitors of HIV replication. | Q34350400 | ||
| HIV-1 integrase inhibitors that compete with the target DNA substrate define a unique strand transfer conformation for integrase | Q35267783 | ||
| FRET analysis reveals distinct conformations of IN tetramers in the presence of viral DNA or LEDGF/p75. | Q35468454 | ||
| Inhibiting HIV-1 integrase by shifting its oligomerization equilibrium | Q35850134 | ||
| HIV integration site selection: analysis by massively parallel pyrosequencing reveals association with epigenetic modifications | Q35914779 | ||
| Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro | Q36538644 | ||
| Comparison of raltegravir and elvitegravir on HIV-1 integrase catalytic reactions and on a series of drug-resistant integrase mutants | Q37139736 | ||
| Targeting HIV: past, present and future | Q37853207 | ||
| The interaction of LEDGF/p75 with integrase is lentivirus-specific and promotes DNA binding | Q38329721 | ||
| In vitro DNA tethering of HIV-1 integrase by the transcriptional coactivator LEDGF/p75. | Q38333373 | ||
| Activity of elvitegravir, a once-daily integrase inhibitor, against resistant HIV Type 1: results of a phase 2, randomized, controlled, dose-ranging clinical trial | Q38375842 | ||
| Overexpression of the lens epithelium-derived growth factor/p75 integrase binding domain inhibits human immunodeficiency virus replication | Q39320408 | ||
| In vitro combination studies of tenofovir and other nucleoside analogues with ribavirin against HIV-1. | Q40428359 | ||
| Discovery of small molecule HIV-1 integrase dimerization inhibitors | Q42719255 | ||
| Identification of the LEDGF/p75 HIV-1 integrase-interaction domain and NLS reveals NLS-independent chromatin tethering | Q42816444 | ||
| Didanosine-ribavirin combination: synergistic combination in vitro, but high potential risk of toxicity in vivo | Q44524871 | ||
| Development of an AlphaScreen-based HIV-1 integrase dimerization assay for discovery of novel allosteric inhibitors | Q45157847 | ||
| Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection | Q46396658 | ||
| Integrase mutants defective for interaction with LEDGF/p75 are impaired in chromosome tethering and HIV-1 replication | Q46458488 | ||
| A 1,536-well [(35)S]GTPgammaS scintillation proximity binding assay for ultra-high-throughput screening of an orphan galphai-coupled GPCR. | Q46553318 | ||
| Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase | Q46843159 | ||
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | HIV | Q15787 |
| P304 | page(s) | 4365-4374 | |
| P577 | publication date | 2012-06-04 | |
| P1433 | published in | Antimicrobial Agents and Chemotherapy | Q578004 |
| P1476 | title | Small-molecule inhibitors of the LEDGF/p75 binding site of integrase block HIV replication and modulate integrase multimerization | |
| P478 | volume | 56 |
| Q38212854 | "Old Dogs with New Tricks": exploiting alternative mechanisms of action and new drug design strategies for clinically validated HIV targets |
| Q34249167 | A critical role of the C-terminal segment for allosteric inhibitor-induced aberrant multimerization of HIV-1 integrase |
| Q27683994 | A new class of multimerization selective inhibitors of HIV-1 integrase |
| Q27644578 | Allosteric Inhibition of Human Immunodeficiency Virus Integrase |
| Q36920004 | Allosteric inhibition of HIV-1 integrase activity |
| Q27677515 | Allosteric integrase inhibitor potency is determined through the inhibition of HIV-1 particle maturation |
| Q38208847 | Allosteric modulation of protein oligomerization: an emerging approach to drug design |
| Q26864619 | Blind prediction of HIV integrase binding from the SAMPL4 challenge |
| Q92637590 | Block-And-Lock Strategies to Cure HIV Infection |
| Q92327007 | Characterization of the Role of Host Cellular Factor Histone Deacetylase 10 during HIV-1 Replication |
| Q42144330 | Concise and Practical Asymmetric Synthesis of a Challenging Atropisomeric HIV Integrase Inhibitor. |
| Q40688076 | Covalent Inhibition of HIV-1 Integrase by N-Succinimidyl Peptides |
| Q37512925 | Critical Contribution of Tyr15 in the HIV-1 Integrase (IN) in Facilitating IN Assembly and Nonenzymatic Function through the IN Precursor Form with Reverse Transcriptase |
| Q39103603 | Different Pathways Leading to Integrase Inhibitors Resistance |
| Q27684242 | Discovery of BI 224436, a Noncatalytic Site Integrase Inhibitor (NCINI) of HIV-1 |
| Q27321347 | Distribution and Redistribution of HIV-1 Nucleocapsid Protein in Immature, Mature, and Integrase-Inhibited Virions: a Role for Integrase in Maturation |
| Q27680666 | Dual inhibition of HIV-1 replication by integrase-LEDGF allosteric inhibitors is predominant at the post-integration stage |
| Q40457748 | Dynamic Oligomerization of Integrase Orchestrates HIV Nuclear Entry |
| Q64231598 | Establishment of latent HIV-1 reservoirs: what do we really know? |
| Q39187770 | Fragment-based discovery of 8-hydroxyquinoline inhibitors of the HIV-1 integrase-lens epithelium-derived growth factor/p75 (IN-LEDGF/p75) interaction |
| Q38725965 | Galectin-3 promotes caspase-independent cell death of HIV-1-infected macrophages |
| Q38124090 | HIV integrase inhibitors: 20-year landmark and challenges |
| Q47329569 | HIV integration sites and implications for maintenance of the reservoir |
| Q35761626 | HIV-1 Gag as an Antiviral Target: Development of Assembly and Maturation Inhibitors |
| Q35170009 | HIV-1 IN/Pol recruits LEDGF/p75 into viral particles |
| Q43714820 | HIV-1 integrase inhibition: looking at cofactor interactions |
| Q38380688 | HIV-1 integrase multimerization as a therapeutic target |
| Q64950510 | HIV-1 integrase tetramers are the antiviral target of pyridine-based allosteric integrase inhibitors. |
| Q38206643 | HIV-1 latency in monocytes/macrophages |
| Q30459386 | HRP2 determines the efficiency and specificity of HIV-1 integration in LEDGF/p75 knockout cells but does not contribute to the antiviral activity of a potent LEDGF/p75-binding site integrase inhibitor |
| Q27026246 | Human immunodeficiency virus (HIV)-1 integration sites in viral latency |
| Q42271398 | Identification of small peptides inhibiting the integrase-LEDGF/p75 interaction through targeting the cellular co-factor |
| Q64086928 | Impact of LEDGIN treatment during virus production on residual HIV-1 transcription |
| Q36781009 | Impact of quaternary structure dynamics on allosteric drug discovery |
| Q39352071 | Inhibiting the HIV integration process: past, present, and the future. |
| Q47554259 | Inhibitors of the integrase-transportin-SR2 interaction block HIV nuclear import |
| Q61813266 | Insight in HIV Integration Site Selection Provides a Block-and-Lock Strategy for a Functional Cure of HIV Infection |
| Q36884128 | Integrating the HIV-1 assembly/maturation pathway |
| Q35770636 | Kuwanon-L as a New Allosteric HIV-1 Integrase Inhibitor: Molecular Modeling and Biological Evaluation |
| Q37035177 | LEDGIN-mediated Inhibition of Integrase-LEDGF/p75 Interaction Reduces Reactivation of Residual Latent HIV |
| Q41454699 | LEDGINs inhibit late stage HIV-1 replication by modulating integrase multimerization in the virions |
| Q38199193 | LEDGINs, non-catalytic site inhibitors of HIV-1 integrase: a patent review (2006 - 2014). |
| Q40809010 | Minimizing the Contribution of Enterohepatic Recirculation to Clearance in Rat for the NCINI Class of Inhibitors of HIV. |
| Q34249653 | Molecular mechanisms of retroviral integration site selection |
| Q31153312 | Molecular modeling study on the allosteric inhibition mechanism of HIV-1 integrase by LEDGF/p75 binding site inhibitors |
| Q92992903 | Multifaceted HIV integrase functionalities and therapeutic strategies for their inhibition |
| Q37574479 | Multimodal mechanism of action of allosteric HIV-1 integrase inhibitors |
| Q92834245 | N-arylnaphthylamines as inhibitors of human immunodeficiency virus integrase - lens epithelium-derived growth factor interactions: theoretical studies |
| Q38077861 | New and investigational antiretroviral drugs for HIV infection: mechanisms of action and early research findings. |
| Q38081866 | Next-generation integrase inhibitors : where to after raltegravir? |
| Q28536951 | Non-catalytic site HIV-1 integrase inhibitors disrupt core maturation and induce a reverse transcription block in target cells |
| Q64087409 | Noncovalent SUMO-interaction motifs in HIV integrase play important roles in SUMOylation, cofactor binding, and virus replication |
| Q53119232 | Novel drugs and treatment strategies for HIV-1. |
| Q33797858 | Preclinical profile of BI 224436, a novel HIV-1 non-catalytic-site integrase inhibitor |
| Q42630471 | Probing Resistance Mutations in Retroviral Integrases by Direct Measurement of Dolutegravir Fluorescence |
| Q40618808 | Pyrazolo[1,5-a]pyrimidine-based macrocycles as novel HIV-1 inhibitors: a patent evaluation of WO2015123182. |
| Q40613330 | Rational Design, Synthesis and Evaluation of Coumarin Derivatives as Protein-protein Interaction Inhibitors |
| Q58760446 | Recent advances in the discovery of small-molecule inhibitors of HIV-1 integrase |
| Q28596842 | Retroviral DNA Integration |
| Q34643561 | Retroviral integrase proteins and HIV-1 DNA integration |
| Q36747516 | Single-cell imaging of HIV-1 provirus (SCIP). |
| Q28554866 | Structural Basis for Inhibitor-Induced Aggregation of HIV Integrase |
| Q52673279 | Structure-function analyses unravel distinct effects of allosteric inhibitors of HIV-1 integrase on viral maturation and integration. |
| Q57822203 | Synthesis and Evaluation of Aryl Quinolines as HIV-1 Integrase Multimerization Inhibitors |
| Q38832507 | TALEN gene editing takes aim on HIV. |
| Q38983286 | TALEN knockout of the PSIP1 gene in human cells: analyses of HIV-1 replication and allosteric integrase inhibitor mechanism |
| Q35060475 | TOX4 and NOVA1 proteins are partners of the LEDGF PWWP domain and affect HIV-1 replication |
| Q42362352 | Targeting Neph1 and ZO-1 protein-protein interaction in podocytes prevents podocyte injury and preserves glomerular filtration function. |
| Q27677549 | The A128T Resistance Mutation Reveals Aberrant Protein Multimerization as the Primary Mechanism of Action of Allosteric HIV-1 Integrase Inhibitors |
| Q45325032 | The HIV-1 integrase-LEDGF allosteric inhibitor MUT-A: resistance profile, impairment of virus maturation and infectivity but without influence on RNA packaging or virus immunoreactivity. |
| Q26849265 | The LEDGF/p75 integrase interaction, a novel target for anti-HIV therapy |
| Q35215018 | The allosteric HIV-1 integrase inhibitor BI-D affects virion maturation but does not influence packaging of a functional RNA genome |
| Q42210738 | The evaluation of statins as potential inhibitors of the LEDGF/p75-HIV-1 integrase interaction. |
| Q34611548 | The mechanism of H171T resistance reveals the importance of Nδ-protonated His171 for the binding of allosteric inhibitor BI-D to HIV-1 integrase |
| Q34683981 | The same site on the integrase-binding domain of lens epithelium-derived growth factor is a therapeutic target for MLL leukemia and HIV. |
| Q40578605 | Virtual screening with AutoDock Vina and the common pharmacophore engine of a low diversity library of fragments and hits against the three allosteric sites of HIV integrase: participation in the SAMPL4 protein-ligand binding challenge |
Search more.